Literature DB >> 24429297

Characteristics of patients with community-acquired bacteremia who have low levels of C-reactive protein (≤20 mg/L).

Fredrikke Christie Knudtzen1, Stig Lønberg Nielsen2, Kim Oren Gradel3, Annmarie Touborg Lassen4, Hans Jørn Kolmos5, Thøger Gorm Jensen5, Pernille Just Vinholt6, Court Pedersen2.   

Abstract

OBJECTIVES: To characterize patients presenting with community-acquired bacteremia and a low C-reactive protein (CRP) plasma level at date of bacteremia.
METHODS: Population-based cohort study. Patient characteristics were compared for three CRP groups (≤20 mg/L, 21-100 mg/L and >100 mg/L) using chi-square test and oneway anova. The 30-day mortality rates were compared using logistic regression analyses.
RESULTS: Of the 2017 patients included, 193 (9.6%) had a CRP ≤20 mg/L. These patients were younger, more likely to be male, overrepresented in the intensive care unit and had more comorbidities. In blood cultures from the low CRP group hemolytic streptococci and coagulase-negative staphylococci were found relatively more common, whereas Streptococcus pneumoniae or Staphylococcus aureus were found relatively less common compared to the other CRP groups. The majority of patients with an initial low CRP mounted a CRP response the following days. The 30-day mortality rate was lower in the low CRP group (13.5%) than in the group with CRP >100 mg/L (20.6%).
CONCLUSIONS: A considerable proportion of patients with community-acquired bacteremia has a normal or low initial CRP level. The plasma CRP level should not be used to rule out serious infection or withhold antibiotic therapy.
Copyright © 2013 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  C-reactive protein; Coagulase-negative staphylococci; Community-acquired bacteremia; Hemolytic streptococci

Mesh:

Substances:

Year:  2013        PMID: 24429297     DOI: 10.1016/j.jinf.2013.10.006

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  6 in total

Review 1.  Periprosthetic Infection in Joint Replacement.

Authors:  Christina Otto-Lambertz; Ayla Yagdiran; Franziska Wallscheid; Peer Eysel; Norma Jung
Journal:  Dtsch Arztebl Int       Date:  2017-05-26       Impact factor: 5.594

2.  Low Completeness of Bacteraemia Registration in the Danish National Patient Registry.

Authors:  Kim Oren Gradel; Stig Lønberg Nielsen; Court Pedersen; Jenny Dahl Knudsen; Christian Østergaard; Magnus Arpi; Thøger Gorm Jensen; Hans Jørn Kolmos; Mette Søgaard; Annmarie Touborg Lassen; Henrik Carl Schønheyder
Journal:  PLoS One       Date:  2015-06-29       Impact factor: 3.240

3.  Patients with community-acquired bacteremia of unknown origin: clinical characteristics and usefulness of microbiological results for therapeutic issues: a single-center cohort study.

Authors:  Johan Courjon; Elisa Demonchy; Nicolas Degand; Karine Risso; Raymond Ruimy; Pierre-Marie Roger
Journal:  Ann Clin Microbiol Antimicrob       Date:  2017-05-19       Impact factor: 3.944

4.  C-reactive protein and albumin kinetics before community-acquired bloodstream infections - a Danish population-based cohort study.

Authors:  O S Garvik; P Póvoa; B Magnussen; P J Vinholt; C Pedersen; T G Jensen; H J Kolmos; A T Lassen; K O Gradel
Journal:  Epidemiol Infect       Date:  2020-02-26       Impact factor: 2.451

5.  A panel of urine-derived biomarkers to identify sepsis and distinguish it from systemic inflammatory response syndrome.

Authors:  Yao Tang; Ning Ling; Shiying Li; Juan Huang; Wenyue Zhang; An Zhang; Hong Ren; Yixuan Yang; Huaidong Hu; Xiaohao Wang
Journal:  Sci Rep       Date:  2021-10-21       Impact factor: 4.379

6.  Characteristics of neonates with culture-proven bloodstream infection who have low levels of C-reactive protein (≦10 mg/L).

Authors:  Mei-Yin Lai; Ming-Horng Tsai; Chiang-Wen Lee; Ming-Chou Chiang; Reyin Lien; Ren-Huei Fu; Hsuan-Rong Huang; Shih-Ming Chu; Jen-Fu Hsu
Journal:  BMC Infect Dis       Date:  2015-08-11       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.